“Feasibility of Personalized Autologous T-Cell Therapy (IMA101) for Advanced Cancer: A Safe and Well-Tolerated Study with Early Signs of Efficacy”

https://pubmed.ncbi.nlm.nih.gov/38114231

The abstract describes a successful feasibility study of a personalized autologous T-cell therapy (IMA101) for advanced cancer patients, which was found to be safe, well-tolerated, and showed early signs of efficacy, justifying further investigation.